Join the Heart Failure group to help and get support from people like you.
Heart Failure News (Page 6)
Related terms: CHF
Half of Medicaid Patients With Diabetes, Heart Failure Do Not Get Follow-Up
THURSDAY, June 8, 2023 – More than half of Medicaid-covered adults with diabetes and heart failure in Alabama did not receive guideline-concordant postdischarge care, according to a study published...
Peer Health Coaching Improves Well-Being in Veterans With CVD Risks
WEDNESDAY, June 7, 2023 – Peer health coaching interventions can create opportunities for well-being improvements, although not physical health improvements, in veterans with cardiovascular disease...
Risk for Heart Failure Higher in Young Adult Cancer Survivors
WEDNESDAY, June 7, 2023 – Young adult (YA) cancer survivors, especially those diagnosed with leukemia or those treated with anthracycline chemotherapy, face an increased risk for heart failure,...
Injectafer Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure
BASKING RIDGE, N.J. & SHIRLEY, N.Y.--(BUSINESS WIRE) June 05, 2023 --Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug...
Hemodynamic Monitoring Beneficial for Chronic Heart Failure
THURSDAY, June 1, 2023 – For patients with chronic heart failure, hemodynamic monitoring with the CardioMEMS-HF system improves the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary...
AHA News: 38-Year-Old Has Had 3 Hearts: 'It's a Third Chance'
WEDNESDAY, May 31, 2023 (American Heart Association News) – Melanie Wickersheim has no memory of the first time her heart gave her trouble. She was an infant, and her pediatric myocarditis – an i...
FDA Approves Inpefa (sotagliflozin) for the Treatment of Heart Failure
THE WOODLANDS, Texas, May 26, 2023 (GLOBE NEWSWIRE) – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has approved Inpefa™ (...
Quadriceps Strength Linked to Lower Risk for Heart Failure After AMI
FRIDAY, May 26, 2023 – A higher level of quadriceps isometric strength (QIS) is associated with a lower risk for developing heart failure after acute myocardial infarction (AMI), according to a...
FDA Approves Furoscix (furosemide injection) for the At-Home Treatment of Congestion Due to Fluid Overload in Chronic Heart Failure
Furoscix demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) – scPharmaceuticals...
US FDA Approves Jardiance (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction
RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 24, 2022 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death ...
FDA Approves Soaanz (torsemide) for Edema Treatment in Patients with Heart Failure and Renal Disease
VIENNA, VA. (PRWEB) JUNE 21, 2021 Sarfez Pharmaceuticals announced today approval by the U.S. Food and Drug Administration (FDA) of the Virginia-based company’s New Drug Application for Soaanz, a o...
Entresto Granted Expanded Indication in Chronic Heart Failure by FDA
EAST HANOVER, N.J., Feb. 16, 2021 -- Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to red...
FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Verquvo, a...
Farxiga Approved in the US for the Treatment of Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction
6 May 2020 – AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (...
FDA Approves Farxiga (dapagliflozin) to Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes
21 October 2019 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure (hHF) in...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Left Ventricular Dysfunction, Cardiovascular Conditions and Disorders
Related drug support groups
lisinopril, metoprolol, warfarin, Coumadin, spironolactone, triamcinolone, Metoprolol Succinate ER, carvedilol, diltiazem, view more... Lasix, Entresto, furosemide, bisoprolol, valsartan, Farxiga, ramipril, Jardiance, digoxin, prazosin, Diovan, nitroglycerin, Coreg